Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2 Cycles vs Standard Rituximab in ITP
NCT02137681Phase 3Withdrawn
- Sponsor
- Shandong University
- Start
- May 2014
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in immune thrombocytopenia (ITP), sponsored by Shandong University. Planned start May 2014; status: withdrawn.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02137681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137681.